Nupathe, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- 14
- Market Cap
- -
- Website
- http://www.nupathe.com
Clinical Trials
8
Active:0
Completed:8
Trial Phases
2 Phases
Phase 1:5
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (62.5%)Phase 3
3 (37.5%)Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine
Phase 1
Completed
- Conditions
- Acute Migraine
- Interventions
- Drug: PROT-CL-NP101-015.01
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02684409
Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults
Phase 1
Completed
- Conditions
- Compare Bioequivalence Patches Previously Used in the NP101-007 Study
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT01381796
- Locations
- 🇺🇸
Prism Research, LLC, Saint Paul, Minnesota, United States
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 514
- Registration Number
- NCT00806546
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT00792103
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: NP101 - Sumatriptan iontophoretic transdermal patchDrug: Placebo
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- NuPathe Inc.
- Target Recruit Count
- 530
- Registration Number
- NCT00724815
- Prev
- 1
- 2
- Next
News
No news found